AN OPEN-LABEL, DOUBLE TYMPANOCENTESIS, SINGLE-CENTER STUDY OF TRIMETHOPRIM SULFAMETOXASOLE IN CHILDREN WITH ACUTE OTITIS MEDIA.
Soley, Carolina MD *; Arguedas, Adriano MD *+; Guevara, Silvia MD *; Loaiza, Cecilia MD *; Rincon, Guillermo MD *; Perez, Alexandra MD *; Brilla, Eduardo MQC ++; Porras, Wendy RN *; Arguedas, Jorge MD *; Sierra, Hernan MD *
[Report] Pediatric Infectious Disease Journal. 26(3):273-274, March 2007.

(Format: HTML, PDF)

Trimethoprim sulfamethoxasole has been recommended for the treatment of acute otitis media. In this double tympanocentesis study, children aged 3 to 48 months with acute otitis media received trimethoprim sulfamethoxasole twice daily (40 mg/kg/d) for 10 days. All children had a baseline tympanocentesis and in culture-positive children, tympanocentesis was repeated at the on-therapy visit. Of 89 children enrolled, 51 (57%) were clinically and bacteriologically evaluable. Bacteriologic eradication was achieved in 80% (42 of 52) of children, and overall clinical response at the end of therapy was 78%. Clinical success was 69% for culture-positive children versus 91% for culture-negative children at baseline tympanocentesis (P = 0.03). In this study, trimethoprim sulfamethoxasole clinical response was unsatisfactory, especially among culture-'positive children.

(C) 2007 Lippincott Williams & Wilkins, Inc.